Centenarians, Metformin & the TAME Trial

Summary

Dr Nir Barzilai, director of the Institute for Aging Research at Einstein College of Medicine, explains the TAME (Targeting Aging with Metformin) trial — the first FDA-approved clinical trial to test a drug that targets aging itself rather than a specific disease.

Key Takeaways

• 1

  TAME is the first clinical trial to target aging as a disease — a landmark regulatory milestone

• 2

  Metformin activates AMPK and inhibits complex I of the mitochondrial electron transport chain

• 3

  Observational data shows metformin users have lower rates of cancer, cardiovascular disease, and dementia

• 4

  The TAME trial will measure a composite of age-related diseases as its primary endpoint

• 5

  If successful, TAME will establish a regulatory pathway for all future longevity drugs

Molecules Discussed

Related Articles